Lactitol

  • TRADE NAME: Pizensy (Braintree Labs)
  • INDICATIONS: Treatment of chronic idiopathic constipation in adults
  • CLASS: Laxative
  • HALF-LIFE: 2.4 hours

FDA APPROVAL DATE: 02/12/2020

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

None known

May reduce the absorption of concomitantly administered oral medications. Administer oral medications at least 2 hours before or 2 hours after administration of lactitol.

Our database has 9 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

CARDIOVASCULAR.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
RESPIRATORY.
OTHER.


Page last updated 06/19/2020

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top